Two Investing Legends Join Forces for One Night ONLY…

and reveal the massive market events that will shape 2020 — and what they recommend you do NOW with your money.

Tue, December 10 at 7:00PM ET
 
 
 
 

28 Biotechnology Stocks to Sell Now

28 Biotechnology Stocks to Sell Now

This week, the overall grades of 28 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Slipping from a C to a D rating, Alexion Pharmaceuticals, Inc. (ALXN) takes a hit this week. Alexion Pharmaceuticals, Inc. engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of ALXN stock.

This week, Blueprint Medicines Corp. (BPMC) drops from a C to a D rating. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of BPMC stock.

Heron Therapeutics Inc (HRTX) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of HRTX stock.

This is a rough week for Coherus BioSciences, Inc. (CHRS). The company’s rating falls to D from the previous week’s C. Coherus BioSciences, Inc. focuses on developing and commercializing biosimilar products worldwide. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of CHRS stock.

Insys Therapeutics, Inc. (INSY) earns a F this week, moving down from last week’s grade of D. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in sales growth, earnings growth, and earnings revisions. For more information, get Portfolio Grader’s complete analysis of INSY stock.

Epizyme, Inc. (EPZM) declines this week from a C to a D. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

Adaptimmune Therapeutics PLC Sponsored ADR (ADAP) slips from a C to a D this week. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of ADAP stock.

T2 Biosystems, Inc. (TTOO) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TTOO stock.

Invitae Corp. (NVTA) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVTA stock.

This week, MiMedx Group, Inc.’s (MDXG) rating worsens to a D from the company’s C rating a week ago. MiMedx Group, Inc. operates as a medical device company. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MDXG stock.

Zafgen, Inc.’s (ZFGN) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZFGN stock.

This week, TRACON Pharmaceuticals, Inc.’s (TCON) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TCON stock.

Amicus Therapeutics, Inc. (FOLD) experiences a ratings drop this week, going from last week’s C to a D. Amicus Therapeutics, Inc. is a biopharmaceutical company which is focused on the discovery, development and commercialization of orally-administered, small molecule drugs known as pharmacological chaperones. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FOLD stock.

OvaScience, Inc. (OVAS) declines this week from a D to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of OVAS stock.

Cara Therapeutics Inc (CARA) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CARA stock.

This is a rough week for ImmunoGen, Inc. (IMGN). The company’s rating falls to F from the previous week’s D. ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMGN stock.

Progenics Pharmaceuticals, Inc. (PGNX) is having a tough week. The company’s rating falls from a C to a D. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets F’s in operating margin growth, earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Trovagene, Inc. (TROV) slips from a C to a D this week. Trovagene, Inc. is developing a non-invasive testing technology using transrenal nucleic acid (TrNA) markers for infectious diseases, prenatal testing, early detection of cancer, and monitoring of organ and cell transplantation. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TROV stock.

Vical Incorporated (VICL) earns a F this week, moving down from last week’s grade of D. Vical Incorporated researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.

This week, Genocea Biosciences, Inc. (GNCA) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of GNCA stock.

Kindred Biosciences, Inc.’s (KIN) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of KIN stock.

Slipping from a C to a D rating, ContraFect Corp. (CFRX) takes a hit this week. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CFRX stock.

Tonix Pharmaceuticals Holding Corp. (TNXP) slips from a D to a F this week. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TNXP stock.

CytRx Corporation (CYTR) is having a tough week. The company’s rating falls from a C to a D. CytRx Corporation is a biopharmaceutical research and development company that specializes in oncology. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CYTR stock.

This week, Conatus Pharmaceuticals Inc.’s (CNAT) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

Galectin Therapeutics Inc.’s (GALT) rating weakens this week, dropping to a F versus last week’s D. Galectin Therapeutics Inc. is a drug development company. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of GALT stock.

Slipping from a D to a F rating, Fibrocell Science, Inc. (FCSC) takes a hit this week. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of FCSC stock.

Neothetics, Inc. (NEOT) declines this week from a C to a D. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NEOT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/06/28-biotechnology-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC